NEWS TODAY
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
Athira Pharma (NASDAQ: ATHA) presented new preclinical data on fosgonimeton at the Alzheimer's Association International Conference (AAIC) 2024.
The data demonstrated fosgonimeton's ability to mitigate amyloid-β-induced toxicity, lower pTau levels, and reduce disruption of protein clearance mechanisms in Alzheimer's disease models. Notably, fosgonimeton showed neuroprotective effects against amyloid-β toxicity in primary neurons, both alone and in combination with lecanemab.
The research suggests that fosgonimeton may attenuate pTau pathology by improving autophagy, a cellular process impaired in Alzheimer's.
These findings support Athira's approach of targeting the neurotrophic HGF system as a potential Alzheimer's treatment and suggest potential benefits of combining fosgonimeton with amyloid-β-targeting monoclonal antibodies.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Lnova : ty for sharing